NYSE:GKOSGlaukos Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Glaukos Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $40.23 +1.23 (+3.15 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$38.61Now: $40.23▼$40.2550-Day Range$36.89MA: $39.75▼$46.8352-Week Range$23.31Now: $40.23▼$84.65Volume547,100 shsAverage Volume810,207 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/ABeta1.77 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.Read More Beat the Market (BTM) Rank™ 2.0 Analyst's Opinion Consensus RatingGlaukos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 4 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.22, Glaukos has a potential upside of 17.4% from its current price of $40.23.Amount of Analyst CoverageGlaukos has only been the subject of 4 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesGlaukos has received 386 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGlaukos has received 303 “underperform” votes. (Add your “underperform” vote.)Community SentimentGlaukos has received 56.02% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote “Outperform” if you believe GKOS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGlaukos does not currently pay a dividend.Dividend GrowthGlaukos does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,153,366.00 in company stock.Percentage Held by InsidersOnly 10.20% of the stock of Glaukos is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Glaukos are expected to grow in the coming year, from ($2.01) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Glaukos is -42.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Glaukos is -42.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGlaukos has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.09 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNYSE:GKOS Previous Symbol CUSIPN/A CIK1192448 Webwww.glaukos.com Phone949-367-9600Debt Debt-to-Equity Ratio0.11 Current Ratio4.53 Quick Ratio3.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$236.98 million Price / Sales7.51 Cash Flow$0.17 per share Price / Cash Flow242.47 Book Value$18.50 per share Price / Book2.17Profitability EPS (Most Recent Fiscal Year)($0.10) Net Income$15.42 million Net Margins-15.65% Return on Equity-6.95% Return on Assets-5.33%Miscellaneous Employees437 Outstanding Shares44,230,000Market Cap$1.78 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable GKOS Rates by TradingView Receive GKOS News and Ratings via Email Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter. Glaukos (NYSE:GKOS) Frequently Asked Questions How has Glaukos' stock been impacted by COVID-19 (Coronavirus)? Glaukos' stock was trading at $38.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GKOS stock has increased by 4.1% and is now trading at $40.23. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Glaukos? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 sell ratings, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Glaukos. When is Glaukos' next earnings date? Glaukos is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Glaukos. How were Glaukos' earnings last quarter? Glaukos Corp (NYSE:GKOS) announced its quarterly earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.44) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.09. The medical instruments supplier had revenue of $55.30 million for the quarter, compared to analyst estimates of $55.05 million. Glaukos had a negative return on equity of 6.95% and a negative net margin of 15.65%. Glaukos's revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the business posted ($0.04) earnings per share. View Glaukos' earnings history. What price target have analysts set for GKOS? 10 analysts have issued 1 year price targets for Glaukos' stock. Their forecasts range from $34.00 to $67.00. On average, they anticipate Glaukos' share price to reach $47.22 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View analysts' price targets for Glaukos. Has Glaukos been receiving favorable news coverage? News headlines about GKOS stock have trended extremely negative on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Glaukos earned a coverage optimism score of -4.3 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Glaukos. Who are some of Glaukos' key competitors? Some companies that are related to Glaukos include Penumbra (PEN), Novocure (NVCR), Tandem Diabetes Care (TNDM), Haemonetics (HAE), Globus Medical (GMED), Inovio Pharmaceuticals (INO), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), Irhythm Technologies (IRTC), NuVasive (NUVA), Inari Medical (NARI), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP) and Cantel Medical (CMD). View all competitors. What other stocks do shareholders of Glaukos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include Alibaba Group (BABA), NVIDIA (NVDA), PTC Therapeutics (PTCT), Paypal (PYPL), Marvell Technology Group (MRVL), Boeing (BA), Micron Technology (MU), Shopify (SHOP), Baidu (BIDU) and Caterpillar (CAT). Who are Glaukos' key executives? Glaukos' management team includes the following people: Mr. Thomas William Burns, CEO, Pres & Director (Age 58)Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)Mr. Richard L. Harrison, Advisor (Age 62)Dr. Mory Gharib Ph.D., Co-Founder When did Glaukos IPO? (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers. What is Glaukos' stock symbol? Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS." Who are Glaukos' major shareholders? Glaukos' stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.04%) and Everence Capital Management Inc. (0.02%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link. View institutional ownership trends for Glaukos. Which major investors are selling Glaukos stock? GKOS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and Thomas William Burns. View insider buying and selling activity for Glaukos. Which major investors are buying Glaukos stock? GKOS stock was bought by a variety of institutional investors in the last quarter, including Everence Capital Management Inc.. View insider buying and selling activity for Glaukos. How do I buy shares of Glaukos? Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Glaukos' stock price today? One share of GKOS stock can currently be purchased for approximately $40.23. How big of a company is Glaukos? Glaukos has a market capitalization of $1.78 billion and generates $236.98 million in revenue each year. The medical instruments supplier earns $15.42 million in net income (profit) each year or ($0.10) on an earnings per share basis. Glaukos employs 437 workers across the globe. What is Glaukos' official website? The official website for Glaukos is www.glaukos.com. How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected] This page was last updated on 7/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
